United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Oops... There was a problem with your request.
- Country "lt" not found.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 281,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "c34230ff-5cef-4146-b934-341bc96874f2",
"title": "Regeneron (REGN) Highlights Promising Phase 3 Trial Results for Libtayo | REGN Stock News",
"description": "Regeneron Pharmaceuticals (REGN) has unveiled comprehensive findings from the Phase 3 C-POST trial concerning Libtayo, a PD-1 inhibitor, for treating patients w",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Regeneron Pharmaceuticals (REGN, Financial) has unveiled comprehensive findings from the Phase 3 C-POST trial concerning Libtayo, a PD-1 inhibitor, for treating...",
"url": "https://www.gurufocus.com/news/2900250/regeneron-regn-highlights-promising-phase-3-trial-results-for-libtayo-regn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008R4.png?20",
"language": "en",
"published_at": "2025-06-01T21:45:36.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 57.822903,
"sentiment_score": 0.124683,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+217 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+312 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+301 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+266 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+320 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+332 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "589e7861-9f23-453b-9411-44199c46acb3",
"title": "Arvinas (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News",
"description": "Arvinas (ARVN), in partnership with Pfizer, has disclosed significant findings from their Phase 3 VERITAC-2 clinical study. This trial assessed the efficacy of",
"keywords": "GuruFocus, Article, News, GuruFocus News, ARVN",
"snippet": "Arvinas (ARVN, Financial), in partnership with Pfizer, has disclosed significant findings from their Phase 3 VERITAC-2 clinical study. This trial assessed the e...",
"url": "https://www.gurufocus.com/news/2900249/arvinas-arvn-announces-promising-phase-3-trial-results-for-vepdegestrant-arvn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIBF.png?20",
"language": "en",
"published_at": "2025-06-01T21:45:29.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARVN",
"name": "Arvinas, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 62.788727,
"sentiment_score": 0.168211,
"highlights": [
{
"highlight": "<em>Arvinas</em> (ARVN, Financial), in p[+311 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+278 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+334 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+237 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+325 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Arvinas</em> <em>In[+315 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> <em>Inc</em> (ARVN) rec[+305 characters]",
"sentiment": -0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> <em>Inc</em> (ARVN) has[+162 characters]",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> (ARVN) Announces Promising Phase 3 Trial Results for Vepdegestrant | ARVN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "792f7702-8791-4fc5-bbc0-d439aeb0b0e1",
"title": "Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News",
"description": "Arcus Biosciences (RCUS) recently showcased initial results for their investigational combination therapy, casdatifan plus cabozantinib, at the 2025 American So",
"keywords": "GuruFocus, Article, News, GuruFocus News, RCUS",
"snippet": "Arcus Biosciences (RCUS, Financial) recently showcased initial results for their investigational combination therapy, casdatifan plus cabozantinib, at the 2025 ...",
"url": "https://www.gurufocus.com/news/2900243/arcus-biosciences-rcus-unveils-promising-data-for-cancer-treatment-rcus-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BEGO.png?20",
"language": "en",
"published_at": "2025-06-01T21:30:12.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "RCUS",
"name": "Arcus Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 102.662895,
"sentiment_score": 0.167056,
"highlights": [
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> (RCU[+292 characters]",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+285 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+255 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+241 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Arcus</em> <em>Bios[+274 characters]",
"sentiment": 0.9413,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> <em>[+284 characters]",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> <em>[+150 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arcus</em> <em>Biosciences</em> (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News",
"sentiment": -0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "1acc11e5-1a8a-403a-ae6d-a3df1cc4a828",
"title": "Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News",
"description": "Allogene Therapeutics' (ALLO) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression. Four out of five patients m",
"keywords": "GuruFocus, Article, News, GuruFocus News, ALLO",
"snippet": "Allogene Therapeutics' (ALLO, Financial) ALLO-316 shows a 31% response rate in advanced renal cell carcinoma with high CD70 expression.\n\nFour out of five patien...",
"url": "https://www.gurufocus.com/news/2900184/allogene-therapeutics-provides-updated-phase-1-data-highlighting-durable-responses-with-allo316-in-heavily-pretreated-advanced-renal-cell-carcinoma-at-asco-allo-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIIE.png?20",
"language": "en",
"published_at": "2025-06-01T16:00:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ALLO",
"name": "Allogene Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 66.951675,
"sentiment_score": 0.376667,
"highlights": [
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em>'[+323 characters]",
"sentiment": 0.2551,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em>,[+164 characters]",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Allogene</em> <em>Therapeutics</em> Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News",
"sentiment": 0.25,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "e6cc881f-ba9b-4eb0-85ba-e82f8acfae6e",
"title": "Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News",
"description": "Replimune's RP1 plus nivolumab shows a 32.9% response rate in anti-PD1 failed melanoma patients. Higher response rates achieved with deep/visceral injec",
"keywords": "GuruFocus, Article, News, GuruFocus News, REPL",
"snippet": "Replimune's RP1 plus nivolumab shows a 32.9% response rate in anti-PD1 failed melanoma patients.\n\nHigher response rates achieved with deep/visceral injections (...",
"url": "https://www.gurufocus.com/news/2900112/replimune-presents-new-analyses-from-the-ignyte-study-of-rp1-plus-nivolumab-in-antipd1-failed-melanoma-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-repl-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BHIM.png?20",
"language": "en",
"published_at": "2025-06-01T15:15:09.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REPL",
"name": "Replimune Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 46.33197,
"sentiment_score": -0.05435,
"highlights": [
{
"highlight": "<em>Replimune</em> <em>Group</em>, <em>I[+303 characters]",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Replimune</em> Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News",
"sentiment": -0.5106,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "bae9bfea-86cc-4839-a79f-e1a5ed578f05",
"title": "Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
"description": "- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resu",
"keywords": "GuruFocus, Article, News, Marketwired, REPL",
"snippet": "- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions -\n\n- Deep/visceral injections, including into the liver and lung, resu...",
"url": "https://www.gurufocus.com/news/2900111/replimune-presents-new-analyses-from-the-ignyte-study-of-rp1-plus-nivolumab-in-antipd1-failed-melanoma-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T15:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REPL",
"name": "Replimune Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 42.686424,
"sentiment_score": -0.03504,
"highlights": [
{
"highlight": "., June 01, 2025 (GLOBE NEWSWIRE) -- <em[+338 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "“The new analyses we presented from th[+314 characters]",
"sentiment": 0.4939,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Replimune</em>\n\n<em>Replimune<[+197 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "Investor Inquiries\n\nChris Brinzey\n\nICR H[+131 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Replimune</em> Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting",
"sentiment": -0.5106,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "e7190a9d-4bef-4bb1-a290-9b3bd0aba658",
"title": "AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News",
"description": "AstraZeneca (AZN) announced encouraging findings from the MATTERHORN Phase III trial, highlighting that perioperative treatment with its drug IMFINZI, when comb",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "AstraZeneca (AZN, Financial) announced encouraging findings from the MATTERHORN Phase III trial, highlighting that perioperative treatment with its drug IMFINZI...",
"url": "https://www.gurufocus.com/news/2900246/astrazeneca-azn-reports-positive-phase-iii-trial-results-for-imfinzi-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:30:33.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.043594,
"sentiment_score": 0.512388,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) an[+267 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.035656,
"sentiment_score": 0.512388,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) an[+267 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "3a514686-6828-4825-8b64-2bbded0d789a",
"title": "AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"description": "AstraZeneca (AZN) has announced promising outcomes from its SERENA-6 Phase III clinical trial, highlighting the efficacy of camizestrant when paired with a cycl",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "AstraZeneca (AZN, Financial) has announced promising outcomes from its SERENA-6 Phase III clinical trial, highlighting the efficacy of camizestrant when paired ...",
"url": "https://www.gurufocus.com/news/2900242/astrazeneca-azn-reports-promising-phase-iii-trial-results-for-camizestrant-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:16:08.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.677715,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.670788,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.670788,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.668396,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.66698,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 50.662872,
"sentiment_score": 0.49295,
"highlights": [
{
"highlight": "<em>AstraZeneca</em> (AZN, Financial) ha[+174 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "837810ab-1dd5-4dc2-b289-a4ac670e543a",
"title": "AstraZeneca's IMFINZI Shows Promising Results in Phase III MATTERHORN Trial | AZN stock news",
"description": "Summary AstraZeneca PLC (AZN) announced positive results from the MATTERHORN Phase III trial, revealing that perioperative treatment with IMFINZI® (durvalumab)",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "Summary\n\nAstraZeneca PLC (AZN, Financial) announced positive results from the MATTERHORN Phase III trial, revealing that perioperative treatment with IMFINZI® ...",
"url": "https://www.gurufocus.com/news/2900105/astrazenecas-imfinzi-shows-promising-results-in-phase-iii-matterhorn-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:01:00.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.968624,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.968416,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.968176,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.96664,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 24.966484,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 24.966322,
"sentiment_score": 0.2979,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+332 characters]",
"sentiment": 0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+236 characters]",
"sentiment": -0.8434,
"highlighted_in": "main_text"
},
{
"highlight": "The significant improvement in EFS and t[+277 characters]",
"sentiment": 0.91,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "215f98a6-7e6d-4ab6-86a6-8a194e4e8230",
"title": "AstraZeneca's Camizestrant Shows Promising Results in SERENA-6 Phase III Trial | AZN stock news",
"description": "Summary AstraZeneca PLC (AZN) announced positive results from the SERENA-6 Phase III trial, demonstrating that camizestrant, in combination with a cyclin-depend",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "Summary\n\nAstraZeneca PLC (AZN, Financial) announced positive results from the SERENA-6 Phase III trial, demonstrating that camizestrant, in combination with a c...",
"url": "https://www.gurufocus.com/news/2900104/astrazenecas-camizestrant-shows-promising-results-in-serena6-phase-iii-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T14:00:50.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.555803,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.555637,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.555426,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.553911,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.55378,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 22.553642,
"sentiment_score": -0.20015,
"highlights": [
{
"highlight": "Summary\n\n<em>AstraZeneca</em> <em>PLC</e[+318 characters]",
"sentiment": 0.4588,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nThe[+261 characters]",
"sentiment": -0.8591,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "9d493cd3-cf5e-4593-8f68-88eb1fbc0a55",
"title": "Gilead (GILD) Presents Yescarta Study Results at ASCO 2025 | GILD Stock News",
"description": "Kite, a subsidiary of Gilead Sciences (GILD), has shared insights from a study assessing the real-world application of Yescarta for patients with relapsed or re",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Kite, a subsidiary of Gilead Sciences (GILD, Financial), has shared insights from a study assessing the real-world application of Yescarta for patients with rel...",
"url": "https://www.gurufocus.com/news/2900245/gilead-gild-presents-yescarta-study-results-at-asco-2025-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-06-01T21:30:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 59.200733,
"sentiment_score": 0.16494,
"highlights": [
{
"highlight": "Kite, a subsidiary of <em>Gilead</em> <e[+312 characters]",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "41e0af8d-674d-4403-8078-de6cc4e13997",
"title": "Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News",
"description": "Protagonist Therapeutics (PTGX), in collaboration with Takeda, has announced encouraging outcomes from its Phase 3 VERIFY trial. This study evaluated rusfertide",
"keywords": "GuruFocus, Article, News, GuruFocus News, PTGX",
"snippet": "Protagonist Therapeutics (PTGX, Financial), in collaboration with Takeda, has announced encouraging outcomes from its Phase 3 VERIFY trial. This study evaluated...",
"url": "https://www.gurufocus.com/news/2900241/protagonist-therapeutics-ptgx-promising-phase-3-results-for-rusfertide-ptgx-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000B4TS.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:57.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PTGX",
"name": "Protagonist Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 85.031105,
"sentiment_score": 0.051475,
"highlights": [
{
"highlight": "<em>Protagonist</em> <em>Therapeutics</e[+250 characters]",
"sentiment": 0.0772,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+304 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+299 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Protagonist</em> <em>Therapeutics</em> (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News",
"sentiment": 0.4019,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "6e668e4f-046c-4023-8bdb-c4e1b03769a0",
"title": "Merck's (MRK) Keytruda-Trodelvy Combo Shows Significant Benefits in Breast Cancer Treatment | MRK Stock News",
"description": "Merck (MRK), internationally referred to as MSD, has unveiled promising findings from a study involving its cancer drug KEYTRUDA in combination with Trodelvy. T",
"keywords": "GuruFocus, Article, News, GuruFocus News, MRK",
"snippet": "Merck (MRK, Financial), internationally referred to as MSD, has unveiled promising findings from a study involving its cancer drug KEYTRUDA in combination with ...",
"url": "https://www.gurufocus.com/news/2900240/mercks-mrk-keytrudatrodelvy-combo-shows-significant-benefits-in-breast-cancer-treatment-mrk-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008C5.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:49.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRK",
"name": "Merck & Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.78658,
"sentiment_score": 0.0285,
"highlights": [
{
"highlight": "<em>Merck</em> (MRK, Financial), interna[+138 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+292 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+60 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "f6461fed-1f8c-43a1-9129-8685d51c96d7",
"title": "Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"description": "Guardant Health (GH) has unveiled significant findings from an extensive study analyzing circulating tumor DNA (ctDNA) in colon cancer patients before chemother",
"keywords": "GuruFocus, Article, News, GuruFocus News, GH",
"snippet": "Guardant Health (GH, Financial) has unveiled significant findings from an extensive study analyzing circulating tumor DNA (ctDNA) in colon cancer patients befor...",
"url": "https://www.gurufocus.com/news/2900235/guardant-health-gh-reveals-key-insights-on-colon-cancer-recurrence-gh-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIF0.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.9498,
"sentiment_score": 0.003086,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+153 characters]",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+294 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+277 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+252 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+316 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Guardant</em> <em>H[+258 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "GH.MX",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.9407,
"sentiment_score": 0.003086,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+153 characters]",
"sentiment": -0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+294 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+277 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+252 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+316 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Guardant</em> <em>H[+258 characters]",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "229decea-ea71-477f-b2b4-7ef6bbbf5dd8",
"title": "GILD: Gilead's Trodelvy Shows Significant Benefit in Breast Cancer Study | GILD Stock News",
"description": "Gilead Sciences (GILD) has announced promising results from a pivotal study involving Trodelvy and Keytruda in treating PD-L1+ metastatic triple-negative breast",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences (GILD, Financial) has announced promising results from a pivotal study involving Trodelvy and Keytruda in treating PD-L1+ metastatic triple-nega...",
"url": "https://www.gurufocus.com/news/2900233/gild-gileads-trodelvy-shows-significant-benefit-in-breast-cancer-study-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-06-01T21:00:37.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILDD.BA",
"name": "GILEAD SCIENCES",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 54.513367,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+289 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+272 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+248 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+57 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.57052,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIS.DE",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.567093,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GILD.MX",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 58.56688,
"sentiment_score": -0.06848,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+327 characters]",
"sentiment": -0.8271,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+298 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+281 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+257 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+66 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "9f01ec79-e7e1-4567-b21a-df84f9d1312e",
"title": "AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"description": "The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky",
"keywords": "GuruFocus, Article, News, GuruFocus News, AZN",
"snippet": "The DESTINY-Gastric04 phase 3 study has yielded promising results for ENHERTU, an innovative HER2-targeting DXd antibody-drug conjugate crafted by Daiichi Sanky...",
"url": "https://www.gurufocus.com/news/2900231/astrazeneca-azn-enhertu-demonstrates-significant-survival-boost-in-gastric-cancer-trial-azn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C00000AGP.png?20",
"language": "en",
"published_at": "2025-06-01T21:00:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZN",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.821407,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "ZEG.DE",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.814663,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNCF",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.814663,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZNN.MX",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.812347,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "AZN.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.810978,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A4J.L",
"name": "AstraZeneca PLC",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 49.80697,
"sentiment_score": 0.457025,
"highlights": [
{
"highlight": "The DESTINY-Gastric04 phase 3 study has [+182 characters]",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+253 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+239 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+228 characters]",
"sentiment": 0.8934,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>AstraZeneca</em> <e[+267 characters]",
"sentiment": 0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> <em>PLC</em> (AZN) [+222 characters]",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AstraZeneca</em> (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News",
"sentiment": -0.2263,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "1bbe7aa3-1bb4-4e76-9eeb-84d2a81e8fbc",
"title": "BeOne Medicines (ONC) Reveals Promising SEQUOIA Trial Results | ONC Stock News",
"description": "BeOne Medicines (ONC) is set to unveil promising findings from its pivotal global Phase 3 SEQUOIA trial, focusing on BRUKINSA, during two rapid oral presentatio",
"keywords": "GuruFocus, Article, News, GuruFocus News, ONC",
"snippet": "BeOne Medicines (ONC, Financial) is set to unveil promising findings from its pivotal global Phase 3 SEQUOIA trial, focusing on BRUKINSA, during two rapid oral ...",
"url": "https://www.gurufocus.com/news/2900238/beone-medicines-onc-reveals-promising-sequoia-trial-results-onc-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000B0F6.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:32.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "BGNE",
"name": "BeiGene, Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 39.831963,
"sentiment_score": 0.1128,
"highlights": [
{
"highlight": "Positive Points\n\n<em>BeiGene</em> <em>Lt[+223 characters]",
"sentiment": 0.8625,
"highlighted_in": "main_text"
},
{
"highlight": "<em>BeiGene</em> <em>Ltd</em> (ONC) has [+292 characters]",
"sentiment": -0.6369,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "ca6df2c2-a4bb-4d5c-bdcf-3c7edc860497",
"title": "TempusAI (TEM) Unveils Fuses Program to Enhance Precision Medicine | TEM Stock News",
"description": "TempusAI (TEM) has introduced its new Fuses program, aiming to utilize its unique dataset to provide critical insights into patient care and medical research. B",
"keywords": "GuruFocus, Article, News, GuruFocus News, TEM",
"snippet": "TempusAI (TEM, Financial) has introduced its new Fuses program, aiming to utilize its unique dataset to provide critical insights into patient care and medical ...",
"url": "https://www.gurufocus.com/news/2900237/tempusai-tem-unveils-fuses-program-to-enhance-precision-medicine-tem-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T21:15:24.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TEM",
"name": "Tempus AI Inc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 32.599243,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "<em>Tempus</em> <em>AI</em> <em>Inc</em>[+138 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "74d9fc07-5fc2-4109-b0af-f305f8b52fd7",
"title": "Crescent Capital BDC (CCAP) Target Price Lowered by BofA to $17 | CCAP Stock News",
"description": "BofA has revised its price target for Crescent Capital BDC (CCAP), reducing it from $20 to $17 while maintaining a Buy rating on the stock. The decision follows",
"keywords": "GuruFocus, Article, News, GuruFocus News, CCAP",
"snippet": "BofA has revised its price target for Crescent Capital BDC (CCAP, Financial), reducing it from $20 to $17 while maintaining a Buy rating on the stock. The decis...",
"url": "https://www.gurufocus.com/news/2900186/crescent-capital-bdc-ccap-target-price-lowered-by-bofa-to-17-ccap-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:30:26.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CCAP",
"name": "Crescent Capital BDC, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 118.61191,
"sentiment_score": 0.367522,
"highlights": [
{
"highlight": "BofA has revised its price target for <e[+237 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+309 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+308 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+270 characters]",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+272 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Crescent</em> <em>C[+184 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crescent</em> <em>Capital</em> <em>B[+320 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crescent</em> <em>Capital</em> <em>B[+192 characters]",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Crescent</em> <em>Capital</em> <em>BDC</em> (CCAP) Target Price Lowered by BofA to $17 | CCAP Stock News",
"sentiment": -0.128,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "928e4db0-f461-4ab2-a0f4-0c435ac4d210",
"title": "Sixth Street (TSLX) Receives Price Target Boost from BofA Analyst | TSLX Stock News",
"description": "BofA analyst Derek Hewett has adjusted the price target for Sixth Street (TSLX), raising it from $23 to $24.50 while maintaining a Buy rating on the stock. Desp",
"keywords": "GuruFocus, Article, News, GuruFocus News, TSLX",
"snippet": "BofA analyst Derek Hewett has adjusted the price target for Sixth Street (TSLX, Financial), raising it from $23 to $24.50 while maintaining a Buy rating on the ...",
"url": "https://www.gurufocus.com/news/2900185/sixth-street-tslx-receives-price-target-boost-from-bofa-analyst-tslx-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-06-01T16:30:18.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TSLX",
"name": "Sixth Street Specialty Lending, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 80.43939,
"sentiment_score": 0.23702,
"highlights": [
{
"highlight": "Wall Street Analysts Forecast\n\nBased on [+329 characters]",
"sentiment": -0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed estimate data can be found[+347 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Based on GuruFocus estimates, the estima[+287 characters]",
"sentiment": 0.8176,
"highlighted_in": "main_text"
},
{
"highlight": "More detailed data can be found on the <[+99 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Positive Points\n\n<em>Sixth</em> <em>Stre[+218 characters]",
"sentiment": 0.8442,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "1e8c7310-92d6-4e68-ae13-a7325305897e",
"title": "Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI",
"description": "Trevi Therapeutics (TRVI) to present topline results from Phase 2b CORAL trial of Haduvio on June 2, 2025. The webcast will provide insights into Haduvi",
"keywords": "GuruFocus, Article, News, GuruFocus News, TRVI",
"snippet": "Trevi Therapeutics (TRVI, Financial) to present topline results from Phase 2b CORAL trial of Haduvio on June 2, 2025.\n\nThe webcast will provide insights into Ha...",
"url": "https://www.gurufocus.com/news/2900234/trevi-therapeutics-to-host-conference-call-and-webcast-on-june-2nd-to-share-topline-results-from-the-phase-2b-coral-trial-of-haduvio-in-patients-with-idiopathic-pulmonary-fibrosis-chronic-cough-trvi",
"image_url": "https://static.gurufocus.com/logos/0C0000BM52.png?20",
"language": "en",
"published_at": "2025-06-01T21:15:10.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TRVI",
"name": "Trevi Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 55.56231,
"sentiment_score": 0.16835,
"highlights": [
{
"highlight": "<em>Trevi</em> <em>Therapeutics</em> (TR[+337 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For those unable to attend the live sess[+158 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For more details, please visit <em>Trevi[+142 characters]",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Trevi</em> <em>Therapeutics</em> to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI",
"sentiment": 0.296,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "2fee0c00-8192-4b43-ab30-36bd3455b570",
"title": "Leonardo S.P.A's (FINMF) Strategic Moves in Aerospace and Defense",
"description": "Quick Summary:\n Leonardo S.P.A (FINMF) launches a New Space Division to expand its satellite capabilities. The firm projects mid-teens growth in profits a",
"keywords": "GuruFocus, Article, News, GuruFocus News, FINMF",
"snippet": "Quick Summary:\n\nLeonardo S.P.A (FINMF, Financial) launches a New Space Division to expand its satellite capabilities.\n\nThe firm projects mid-teens growth in pro...",
"url": "https://www.gurufocus.com/news/2900223/leonardo-spas-finmf-strategic-moves-in-aerospace-and-defense",
"image_url": "https://static.gurufocus.com/logos/0C00000QFH.png?20",
"language": "en",
"published_at": "2025-06-01T20:55:44.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "FINMY",
"name": "Leonardo S.p.a.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 48.41721,
"sentiment_score": 0.733867,
"highlights": [
{
"highlight": "Quick Summary:\n\n<em>Leonardo</em> <em>S.[+245 characters]",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Leonardo S.P.A's Strategic Expansion\n\nIt[+323 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Leonardo</em> <em>S.P.A</em> anticip[+272 characters]",
"sentiment": 0.9403,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "FINMF",
"name": "Leonardo S.p.a.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 100.68573,
"sentiment_score": 0.5824,
"highlights": [
{
"highlight": "Quick Summary:\n\n<em>Leonardo</em> <em>S.[+254 characters]",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "Leonardo S.P.A's Strategic Expansion\n\nIt[+332 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Leonardo</em> <em>S.P.A</em> anticip[+272 characters]",
"sentiment": 0.9403,
"highlighted_in": "main_text"
},
{
"highlight": "Leonardo S.P.A's (<em>FINMF</em>) Strategic Moves in Aerospace and Defense",
"sentiment": 0.128,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "465f611a-b3a4-4082-bc1d-cbb960c94b56",
"title": "Seagate Technology (STX) Surges Over 29% on Revenue Guidance Boost and Share Buyback",
"description": "Key Takeaways:\n Seagate Technology (STX) shares surged by 29.56% in May, driven by revised upbeat revenue guidance and AI storage demand. The company anno",
"keywords": "GuruFocus, Article, News, GuruFocus News, STX",
"snippet": "Key Takeaways:\n\nSeagate Technology (STX, Financial) shares surged by 29.56% in May, driven by revised upbeat revenue guidance and AI storage demand.\n\nThe compan...",
"url": "https://www.gurufocus.com/news/2900222/seagate-technology-stx-surges-over-29-on-revenue-guidance-boost-and-share-buyback",
"image_url": "https://static.gurufocus.com/logos/0C000008YL.png?20",
"language": "en",
"published_at": "2025-06-01T20:55:36.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "STX",
"name": "Seagate Technology plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 70.54289,
"sentiment_score": 0.454671,
"highlights": [
{
"highlight": "Key Takeaways:\n\n<em>Seagate</em> <em>Tec[+228 characters]",
"sentiment": 0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "Seagate's Stock Surge: Understanding the[+151 characters]",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "Analyst Price Targets and Recommendation[+228 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Investors can explore more detailed esti[+260 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Assessing the GF Value and Future Outloo[+224 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "More comprehensive data is available on [+220 characters]",
"sentiment": 0.6326,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Seagate</em> <em>Technology</em> (STX) Surges Over 29% on Revenue Guidance Boost and Share Buyback",
"sentiment": 0.5994,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 517,
"sentiment_avg": 0.21579323016283944
}
]
}
Other details
Entity count
- 32,649